Investigating how Notch signaling affects key genes in triple-negative breast cancer
Notch-driven Epigenetic Program of MYC and CCND1 in Triple-Negative Breast Cancer
This study is looking at how a specific signaling process in cells, called Notch signaling, affects the growth of triple-negative breast cancer, with the hope of finding new treatment options for patients who haven't had success with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10993107 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of Notch signaling in triple-negative breast cancer (TNBC), a type of breast cancer that currently lacks effective targeted treatments. The study aims to explore how Notch signaling activates important cancer-related genes such as MYC and CCND1, which are involved in tumor growth and cell division. By examining the mechanisms behind Notch signaling and its impact on these genes, the research seeks to identify new therapeutic strategies for patients with therapy-resistant TNBC. Patients may benefit from insights that could lead to more effective treatments tailored to their specific cancer profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer, particularly those who have not responded to existing treatments.
Not a fit: Patients with non-triple-negative breast cancer or those who have already responded well to current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new targeted therapies for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promise in targeting Notch signaling in cancer, but this specific approach in TNBC is relatively novel and untested.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Faryabi, Robert Babak — University of Pennsylvania
- Study coordinator: Faryabi, Robert Babak
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.